DA
BIOL

DCM Advisors’s Biolase, Inc. BIOL Stock Holding History

DCM Advisors’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$6K – 233
2021
Q4 		$6K Sell
7
-32
-82% -$40.4K ﹤0.01% 219
2021
Q3 		$62K Hold
39
– – 0.02% 261
2021
Q2 		$68K Sell
39
-9
-19% -$16.7K 0.04% 223
2021
Q1 		$101K Buy
+48
New +$118K 0.06% 217

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
ZF
Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

DCM Advisors's BIOL Position: Q1 2022 in Review

DCM Advisors sold out of Biolase, Inc. (BIOL) in Q1 2022, closing a stake of 7 shares — an estimated $6K sold.

DCM Advisors first reported a position in BIOL in Q1 2021 and held it in 4 quarters. The position peaked at $101K in Q1 2021. 28 funds tracked by Wall St. Rank hold BIOL as of Q1 2022.

  • DCM Advisors reported no remaining Biolase, Inc. position as of Q1 2022 after selling out during the quarter.
  • DCM Advisors sold 7 Biolase, Inc. shares in Q1 2022, an estimated $6K.
  • DCM Advisors first reported a position in Biolase, Inc. in Q1 2021 and held it in 4 quarters.
  • DCM Advisors's Biolase, Inc. position peaked at $101K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2022.

Based on DCM Advisors's 13F filing for Q1 2022, filed 9 May 2022.